Modified AAV caps and their uses

By optimizing the rAAV capsid by inserting specific polypeptide sequences into the AAV9 capsid, the problem of uneven gene delivery in muscle tissue was solved, the gene expression efficiency and distribution in muscle tissue were improved, and the dosage was reduced.

CN123062541APending Publication Date: 2026-11-10SOLID BIOSCIENCES INC
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202610816087.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2020-05-08
Filing Date
2020-10-09
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing recombinant adeno-associated virus (rAAV) vectors exhibit uneven gene delivery efficiency and distribution in muscle tissue, necessitating higher doses and insufficient distribution via intravenous administration.

Method used

By inserting specific polypeptide sequences, such as SEQ ID NO: 1 to SEQ ID NO: 12, at specific locations on the wild-type AAV9 VP1 capsid, modified mAAV capsids are formed, optimizing their targeting and expression efficiency in muscle tissue.

Benefits of technology

This approach enables efficient expression of genes of interest (GOI) in cardiac, skeletal, and smooth muscle, while reducing expression in the liver, thus improving the efficacy of gene therapy and reducing the required dosage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123062541A_ABST
    Figure CN123062541A_ABST
Patent Text Reader

Abstract

This article relates to modified AAV capsids and their uses. Specifically, the methods described herein provide a modified VP1 capsid capable of preferentially targeting a gene of interest (GOI) in muscle tissue, and a recombinant adeno-associated virus (rAAV) having a GOI encapsulated in the modified VP1 capsid, and their uses.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention is a divisional application of a PCT patent application filed in China with Chinese patent application number 202080086045.9, entitled "Modified AAV Capsule and Its Use Thereof", and international filing date of October 9, 2020.

[0002] Citation of relevant applications This application claims the filing date benefits of U.S. Provisional Patent Application No. 62 / 913,223, filed October 10, 2019, and U.S. Provisional Patent Application No. 63 / 021,712, filed May 8, 2020, the entire contents of which are incorporated herein by reference. Technical Field

[0003] This article relates to a modified VP1 capsid capable of preferentially targeting the expression of a gene of interest (GOI) in muscle tissue, and a recombinant adeno-associated virus (rAAV) having a GOI encapsulated in the modified VP1 capsid, and their uses. Background Technology

[0004] Recombinant adeno-associated virus (rAAV) vectors hold promise as a major platform for in vivo gene delivery. A variety of rAAV vectors enable delivery to multiple tissues, including the muscular system, for the treatment of various genetic and other complex diseases. Some natural serotypes, as well as engineered rAAV capsids, exhibit enhanced, widespread biodistribution in muscle, which can reduce the total dose required.

[0005] Previously, gene delivery to muscle was performed by directly injecting rAAV vectors into the muscle. Recently, intravenous (IV) administration of rAAV has become increasingly common to promote its distribution to various muscle types and is now the preferred route of administration in some clinical trials. Summary of the Invention

[0006] One aspect of the present invention provides a modified adeno-associated virus (mAAV) capsid polypeptide comprising a polypeptide selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 12, wherein the polypeptide is inserted between residues 588 and 589 of the wild-type AAV9 VP1 capsid, or between two corresponding residues of the non-AAV9 wild-type Clad F (e.g., AAVhu.32), wild-type Clad A (e.g., AAV1), or wild-type Clad E (e.g., AAV8, AAVrh.10, or AAVrh.74) VP1 capsid. In other words, apart from the polypeptide inserted between residues 588 and 589 of the wild-type AAV9 VP1 capsid or between any two corresponding residues of the non-AAV9 wild-type Clad F (e.g., AAVhu.32), wild-type Clad A (e.g., AAV6), or wild-type Clad E (e.g., AAV8, AAVrh.10, or AAVrh.74) VP1 capsid, there are no other sequence variations in the wild-type Clad F (e.g., AAV9 or AAVhu.32), wild-type Clad A (e.g., AAV6), or wild-type Clad E (e.g., AAV8, AAVrh.10, or AAVrh.74) VP1 capsid.

[0007] In other words, the present invention provides a modified adeno-associated virus (mAAV) capsid polypeptide comprising a polypeptide inserted between residues 588 and 589 of the wild-type AAV9 VP1 capsid or between two corresponding residues of the non-AAV9 wild-type Clad F (e.g., AAVhu.32), wild-type Clad A (e.g., AAV6), or wild-type Clad E (e.g., AAV8, AAVrh.10, or AAVrh.74) VP1 capsid, wherein the polypeptide inserted between residues 588 and 589 of the wild-type AAV9 VP1 capsid or between two corresponding residues of the non-AAV9 wild-type Clad F (e.g., AAVhu.32), wild-type Clad A (e.g., AAV6), or wild-type Clad E (e.g., AAV8, AAVrh.10, or AAVrh.74) VP1 capsid comprises, or is substantially composed of, the amino acid sequence of any of SEQ ID NO: 1 to SEQ ID NO: 12.

[0008] In some embodiments, the mAAV capsid polypeptide comprises the polypeptide of SEQ ID NO: 1, SEQ ID NO: 11, or SEQ ID NO: 12.

[0009] In other words, one specific aspect of the present invention provides a modified adeno-associated virus (mAAV) capsid polypeptide comprising, substantially comprising, or consisting of the polypeptide of SEQ ID NO: 1.

[0010] In one relevant specific aspect, the present invention provides a modified adeno-associated virus (mAAV) capsid polypeptide comprising, substantially comprising, or consisting of the polypeptide of SEQ ID NO: 11.

[0011] In one related specific aspect, the present invention provides a modified adeno-associated virus (mAAV) capsid polypeptide comprising, substantially comprising, or consisting of the polypeptide of SEQ ID NO: 12.

[0012] Another aspect of the present invention provides a recombinant adeno-associated virus (rAAV, such as recombinant AAV6, AAV8, AAVrh.74 or AAV9) comprising any of the test mAAV capsid polypeptides described herein.

[0013] In some respects, the VP1 capsid of rAAV is composed of or substantially composed of any mAAV capsid polypeptide of the present invention.

[0014] In some implementations, rAAV contains a gene of interest (GOI) flanked by a pair of AAV ITR sequences.

[0015] In some implementations, the pair of AAV ITR sequences is an AAV2, AAV6, AAV8, AAVrh.74, or AAV9 ITR sequence.

[0016] In some implementations, genes of interest (GOIs) include: genes responsible for or defective in LGMD2E (limb-girdle muscular dystrophy type 2E), LGMD2D (limb-girdle muscular dystrophy type 2D), LGMD2C (limb-girdle muscular dystrophy type 2C), LGMD2B (limb-girdle muscular dystrophy type 2B), LGMD2L (limb-girdle muscular dystrophy type 2L), and LGMD2I (limb-girdle muscular dystrophy type 2I); or genes related to Naglu (α-N-acetylglucosamine glycosidase, for Sanfilippo syndrome or mucopolysaccharidosis type IIIB (MPS IIIB)), sulfonamide SGSH (for mucopolysaccharidosis type IIIA or MPS IIIA), factor IX, factor VIII, myotubulein 1 (MTM1), motor neuron survival (SMN, for spinal muscular atrophy or SMA), GalNActransferase GALGT2, and calpain-3. The gene or coding sequence of (CAPN-3), acid α-glucosidase (GAA, for Pompe disease), α-galactosidase A or GLA (for Fabry disease), glucocerebrosidase, dystrophin or microdystrophin.

[0017] In some implementations, GOI encodes a small dystrophin.

[0018] In some embodiments, the micro dystrophin is the micro dystrophin described in US7,906,111, US7,001,761, US7,510,867, US6,869,777, US8,501,920, US7,892,824, PCT / US2016 / 013733 or US10,166,272.

[0019] In some embodiments, the miniature dystrophin comprises the coding sequences of the R16 and R17 spectrin-like repeat sequences of the full-length dystrophin (such as the coding sequences described in US7,892,824).

[0020] In some embodiments, the miniature dystrophin comprises the coding sequence of the R1, R16, R17, R23, and R24 spectrin-like repeat sequences of the full-length dystrophin, or the miniature dystrophin described in PCT / US2016 / 013733 or US10,479,821.

[0021] In some implementations, the GOI is operatively linked to a transcriptional regulatory box, such as a muscle-specific promoter (e.g., the CK8 promoter or the cardiac troponin T (cTnT) promoter).

[0022] In some embodiments, GOI is a miniature dystrophin gene encoding a protein comprising, from N-terminus to C-terminus: an N-terminal actin-binding (AB1) domain, a β-dystrophin-binding domain, a hinge 1 domain (H1), a spectrin-like repeat unit domain comprising five spectrin-like repeat sequences including spectrin-like repeat sequence 1 (SR1), spectrin-like repeat sequence 16 (SR16), spectrin-like repeat sequence 17 (SR17), spectrin-like repeat sequence 23 (SR23), and spectrin-like repeat sequence 24 (SR24), and a hinge 4 domain (H4), wherein the miniature dystrophin gene is operatively linked to the muscle-specific human muscle creatine kinase CK8 promoter (e.g., SEQ ID NO:19 of US10,479,821), and wherein GOI is flanked by a pair of AAV2 ITR (inverted terminal repeat) sequences.

[0023] Another aspect of the present invention provides a polynucleotide encoding the modified adeno-associated virus (mAAV) capsid polypeptide of the present invention, having at least 95%, 96%, 97%, 98%, or 99% identical polypeptide sequence to the capsid polypeptide.

[0024] In some implementations, polynucleotides are codon-optimized due to mammalian expression.

[0025] Another aspect of the present invention provides a carrier comprising the polynucleotide of the present invention.

[0026] In some implementations, the vector is a capsid or viral vector (such as an HSV vector or an AAV vector).

[0027] Another aspect of the invention provides a cultured host cell comprising: (a) a recombinant nucleic acid molecule encoding: (1) the modified adeno-associated virus (mAAV) capsid polypeptide of the present invention, or (2) a polypeptide that is at least 95%, 96%, 97%, 98% or 99% identical to (1), wherein the recombinant nucleic acid molecule optionally further comprises a heterologous non-AAV sequence; or, (b) the recombinant adeno-associated virus (rAAV) of the present invention.

[0028] Another aspect of the invention provides a method for treating a disease or condition such as muscular dystrophy in a subject with this need, the method comprising administering to the subject a therapeutically effective amount of any of the rAAVs of the invention.

[0029] In some implementations, when compared with other identical reference rAAVs having a wild-type AAV9 VP1 capsid, the GOI of rAAVs is preferentially expressed in cardiac, skeletal, and / or smooth muscle (e.g., smooth muscle in the diaphragm).

[0030] In some embodiments, the GOI of the rAAV is expressed in the liver at a statistically significantly lower level compared to other identical reference rAAVs having a wild-type AAV9 VP1 capsid.

[0031] In some implementations, muscular dystrophy is referred to as DMD (Duchenne muscular dystrophy) or BMD (Becker muscular dystrophy).

[0032] In some implementations, (1) the muscular dystrophy is LGMD2E (limb-girdle muscular dystrophy type 2E), LGMD2D (limb-girdle muscular dystrophy type 2D), LGMD2C (limb-girdle muscular dystrophy type 2C), LGMD2B (limb-girdle muscular dystrophy type 2B), LGMD2L (limb-girdle muscular dystrophy type 2L), LGMD2I (limb-girdle muscular dystrophy type 2I), or spinal muscular atrophy or SMA; (2) the disease or condition is Sanfilippo syndrome or mucopolysaccharidosis type IIIB (MPSIIIB), mucopolysaccharidosis type IIIA or MPS IIIA, Pompe disease or Fabry disease; or, (3) the disease or condition is characterized or caused by a gene defect in the gene encoding factor IX, factor VIII, myotubulein 1 (MTM1), GalNAc transferase GALGT2, calpain-3 (CAPN-3), or glucocerebrosidase.

[0033] Another aspect of the present invention provides a method for producing rAAV, wherein the rAAV comprises any of the mAAV capsid polypeptides of the present invention, the method comprising introducing a GOI encoding a pair of ITR sequences on its flanking sides into an rAAV vector to produce or encapsulate a cell line expressing any of the mAAV capsid polypeptides of the present invention.

[0034] In some embodiments, the cell lines are produced or packaged by infection with an HSV vector encoding the mAAV capsid polypeptide of the present invention.

[0035] In some embodiments, the production or encapsulation of cell lines is performed by transfection with the coding sequence of the mAAV capsid polypeptide of the present invention.

[0036] In some implementations, the cell lines produced or packaged are HEK293 cells, A549 cells, or HeLa cells.

[0037] It should be understood that any embodiment of the present invention, including those described only in the embodiments or under one aspect of the invention, may be combined with any one or more other embodiments of the invention, unless expressly denied or not applicable. Attached Figure Description

[0038] Figures 1A to 1E The in vitro potency assay shows a comparison of AAV9 and AAV8 with the test AAV-SLB101 capsid (abbreviated as “AAV-101” in the figure or referred to elsewhere as “SLB101”, “SLB-101” or a variant thereof).

[0039] Figure 2A and 2B The in vitro titer assays comparing AAV9 and AAV8 with the tested AAV-SLB101 capsid were performed on both C2C12 cells and patient-derived DMD Mouly cells.

[0040] Figures 3A to 3C The results showed that, compared with AAV9, the test rAAV capsid exhibited good biodistribution and high levels of microdystrophin expression in all three types of muscle and liver tissues, while there was no difference in expression in peripheral tissues such as lung, spleen, kidney and brain.

[0041] Figure 4 The production yield of the novel capsid of the present invention compared to the wild-type AAV9 capsid is shown. For AAV yield from triple transfection of adherent 293T cells, amplification plates of the tested AAV capsids (AAV-SLB101 to AAV-SLB112) were compared with wild-type AAV9 and purified by stepwise iodine ultracentrifugation. Two additional modified capsids, AAV-SLB113 and AAV-SLB114 (see below), are also described. Figure 6 Sequence alignment (in the sequence) is also included in this comparison.

[0042] Figures 5A to 5C The in vitro characterization results of the tested modified AAV capsid are shown for comparison with wild-type AAV9 capsid in C2C12 cells. Specifically, Figure 5A The quantification of AAV capsid binding to the cell surface of C2C12 cells was shown, as measured by qPCR of DNA isolated after incubation at 4°C for 1 hour. AAV-SLB101 (p < 0.0001), AAV-SLB-112 (p < 0.01), and AAV-SLB-114 (p < 0.001) bound to C2C12 cells significantly more than AAV9. Statistical analysis was performed using a standard one-way ANOVA. Figure 5BThe quantification of AAV uptake into C2C12 cells was demonstrated by qPCR measurement of DNA isolated after incubation at 4°C for 1 hour and then at 37°C for another 1 hour. AAV-SLB101, 102, 108, 111, 112, 113, and 114 were uptaken by C2C12 cells significantly more than AAV9 (p < 0.0001). Statistical analysis was performed using a standard one-way ANOVA. Figure 5C In this study, C2C12 cells were transduced using vectors expressing dystrophin encapsulated in AAV9, AAV-SLB101, and thirteen other capsids (AAV-SLB102 to AAV-SLB114). Cells were harvested 96 hours post-transduction, and dystrophin expression was measured. Data were normalized to AAV9, and fold changes are indicated in the table. AAV-SLB101, 102, 111, 112, and 113 showed the highest dystrophin expression relative to AAV9 (p < 0.0001), while AAV-SLB109 and 114 resulted in only slightly higher expression than AAV9 (p < 0.001). Statistical analysis was performed using standard one-way ANOVA.

[0043] Figure 6 This shows sequence alignments of wild-type AAV9 with SLB101 to SLB114 (lines 2 to 16, respectively) and the common sequence (the sequence shown by the top line). It also includes smaller regional alignments between wild-type AAV9, SLB101, SLB-113, and SLB114.

[0044] Figure 7 The data shows the biodistribution of AAV9 variants with variant capsids SLB-101, SLB-102, SLB-113, and SLB-114 in the heart, quadriceps muscle, diaphragm, and liver, compared to wild-type AAV9. * indicates different levels of statistical significance.

[0045] Figure 8 The data shows the expanded biodistribution of AAV9 variants with variant capsids SLB-101, SLB-102, SLB-113, and SLB-114 in the lungs, kidneys, brain, and spleen compared to wild-type AAV9. * indicates different levels of statistical significance.

[0046] Figure 9 The expression of microdystrophin encoded by AAV9 vectors with variant AAV9 capsids SLB-101, SLB-102, SLB-113, and SLB-114 was shown compared to wild-type AAV9. Statistical significance at different levels is indicated by "*". Detailed Implementation

[0047] 1. Overview The aspects described herein provide optimized delivery of genes of interest (GOIs) based in part on optimized rAAV capsids that exhibit superior biodistribution compared to wild-type capsids. Such rAAVs with modified VP1 capsids can be used to preferentially deliver GOIs to muscle tissue at higher expression levels and / or lower doses, thus facilitating more successful gene therapies targeting muscle tissue, such as skeletal muscle, cardiac muscle, and / or smooth muscle tissue.

[0048] In particular, according to one aspect of the invention, this document provides modified AAV capsids and methods for selecting AAV capsids capable of preferentially delivering GOI to muscle tissue and muscle cell types.

[0049] According to another aspect of the invention, this document provides a method for selecting potentially infectious AAV capsids to potentially reduce the effective AAV dose required for successful gene therapy.

[0050] As rAAV drug products advance clinically, analytical tools are needed to characterize these complex products. Examples include the detection and quantification of mammalian cell host or viral helper DNA via PCR, qPCR, variant gel electrophoresis, and Southern blotting. The development and validation of these and other assays will enable complete characterization of rAAV vectors. Therefore, another aspect of the invention provides analytical tools for characterizing test rAAV capsids, vectors, and products such as those described in the examples.

[0051] Another aspect of the invention provides an in vitro potency assay as a clinical tool for developing test rAAV capsids and vectors. rAAV vectors with capsids of various natural serotypes and engineered capsids are compared to evaluate their efficacy for systemic administration and their potential for developing treatments for indications of diseases treatable by gene therapy, such as Duchenne muscular dystrophy (DMD). In applications requiring high-dose systemic administration of vectors, such as in Duchenne muscular dystrophy, these analytical tools and assays have the potential to further characterize and improve rAAV products, and thus improve safety and efficacy of gene-patented therapies.

[0052] The details of the invention are further described below.

[0053] 2. Modified VP1 capping The modified AAV9 VP1 capsid protein of the present invention has a short peptide of about 7 to 13 residues inserted between residues Q588 and A589 of the wild-type AAV9 VP1 capsid protein. In some embodiments, said short peptide is any one of SEQ ID NO: 1 to SEQ ID NO: 12.

[0054] RGDLGLS (SEQ ID NO: 1) (also known as SLB101) RGDMSRE (SEQ ID NO: 2) (also known as SLB102) GEARISA (SEQ ID NO: 3) (also known as SLB103) ESGLSQS (SEQ ID NO: 4) (also known as SLB104) EYRDSSG (SEQ ID NO: 5) (also known as SLB106) DLGSARA (SEQ ID NO: 6) (also known as SLB106) SGNSGAA (SEQ ID NO: 7) (also known as SLB107) CDCRGDCFC (SEQ ID NO: 8) (also known as SLB108) NDVRSAN (SEQ ID NO: 9) (also known as SLB109) NDVRAVS (SEQ ID NO: 10) (also known as SLB1010) GGGRGDLGLSGGG (SEQ ID NO: 11) (also known as SLB1011) GGSRGDLGLSGGS (SEQ ID NO: 12) (also known as SLB1012) Two other sequences with similar insertional modifications but different surrounding / flank sequences are called SLB113 and SLB114 (see [link to SLB114]). Figure 6 ).

[0055] The wild-type AAV9 VP1 capsid protein sequence is known in the art and is copied below. Residues Q588 and A589 inserted between SEQ ID NO:1 to SEQ ID NO:12 are shown with double underscores.

[0056] MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPV EQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHF SPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLI DQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSA QA QAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL (SEQ ID NO: 13) In some embodiments, the modified AAV9 VP1 capsid of the present invention has a polypeptide of SEQ ID NO: 1 inserted between residues Q588 and A589 (both double-underlined) of SEQ ID NO: 13. Bold italic ), as shown below: MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPV EQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHF SPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLI DQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSA Q RGDLGLS A QAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL (SEQ IDNO: 14) In some embodiments, the modified AAV9 VP1 capsid of the present invention has a polypeptide of SEQ ID NO: 11 inserted between residues Q588 and A589 (both double-underlined) of SEQ ID NO: 13. Bold italic ), as shown below: MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPV EQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHF SPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLI DQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSA Q GGGRGDLGLSGG G A QAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL(SEQ ID NO: 15) In some embodiments, the modified AAV9 VP1 capsid of the present invention has a polypeptide of SEQ ID NO: 12 inserted between residues Q588 and A589 (both double-underlined) of SEQ ID NO: 13. Bold italic ), as shown below: MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPV EQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHF SPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLI DQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSA Q GGSRGDLGLSGG S A QAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL(SEQ ID NO: 16) The modified AAV9 VP1 capsid of the present invention enables preferential targeting and expression of GOIs from rAAV encapsulated in such modified AAV9 VP1 capsids, particularly in muscular tissues including cardiac muscle (i.e., the muscle in the heart), skeletal muscle (e.g., the quadriceps) and / or smooth muscle (e.g., the diaphragm).

[0057] To avoid being bound by any particular theory, altering the wild-type amino acid sequence in the AAV9 VP1 capsid near the insertion site (i.e., residues 1, 2, 3, 4, 5, 6, 7, or 8 at the N-terminus of Q588 and / or Q588 itself, and / or residues 1, 2, 3, 4, 5, 6, 7, or 8 at the C-terminus of A589 and / or A589 itself) may affect (e.g., negatively impact) tissue targeting and / or GOI expression levels in the target tissue. One embodiment of this effect or alteration, when compared to AAV encapsulated with a test-modified AAV9 VP1 capsid sequence that fully preserves and includes both residues near Q588 and A589, could be tissue infection rate or expression levels in a desired and specific tissue, such as any muscle tissue like cardiac, skeletal, and / or smooth muscle tissue.

[0058] In some embodiments, GOI preferential expression is at least 50%, 100% (i.e., 2-fold), 3-fold, 5-fold, 10-fold, 12-fold, 15-fold, 20-fold, 22-fold, 25-fold, 30-fold, 50-fold, 75-fold, or 100-fold or higher compared to other identical rAAV constructs using only wild-type AAV9 capsids. In some embodiments, the fold increase is based on in vitro and / or in vivo assays measured substantially as described in the examples (which are incorporated herein by reference for clarity and to avoid redundancy). For example, in some embodiments, the in vitro cell line is C2C12 cells or Mouly cells derived from a patient. In some embodiments, the in vivo assay is performed in the DMD. mdx Execution in a mouse model.

[0059] In some embodiments, the modified adeno-associated virus (mAAV) capsid polypeptide is not based on AAV9, but rather on the VP1 capsid of a non-AAV9 wild-type Clad F (e.g., AAVhu.32), wild-type Clad A (e.g., AAV6), or wild-type Clad E (e.g., AAV8, AAVrh.10, or AAVrh.74). That is, a polypeptide selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 12 is inserted between corresponding residues of the VP1 capsid of a non-AAV9 wild-type Clad F (e.g., AAVhu.32), wild-type Clad A (e.g., AAV6), or wild-type Clad E (e.g., AAV8, AAVrh.10, or AAVrh.74).

[0060] As used herein, “corresponding residue” refers to the residues of the VP1 capsid of non-AAV9 wild-type Clad F AAV (e.g., AAVhu.32), wild-type Clad A AAV (e.g., AAV6), or wild-type Clad E AAV (e.g., AAV8, AAVrh.10, AAVrh.37, or AAVrh.74) that are aligned with residues 588 and 589 of the wild-type AAV9 VP1 capsid, respectively.

[0061] As used in this article, non-AAV9 wild-type Clad F AAVs include AAVhu.32. Wild-type Clad A AAVs include AAV1 / 6, AAVhu.48R2, AAVhu.48R3, and AAVhu.44R3. Wild-type Clad E AAVs include AAV8, AAVhu.37, AAVrh.10, AAVpi.2, AAVrh.64R1, AAVrh.64R2, AAVrh.2R, AAVrh.74, and AAVrh.43.

[0062] For example, the insertion points in representative Clad A AAV6, Clad E AAV8, and AAVrh.74, as well as Clad FAAV9 and AAVhu.32, are shown below. Note that due to sequence differences, AAV8 residues N590 and T591 “correspond” to AAV9 residues Q588 and A589, respectively. 3. Genes of Interest (GOI) in rAAV and treatable diseases The recombinant AAV vector of the present invention, having a modified VP1 capsid, can carry any gene of interest (GOI) for use in treating diseases or conditions through gene therapy. The GOI can be any gene or coding sequence within the rAAV encapsulation capability, for example, about 4 to 5 kb, or about 4.7 kb (including the ITR sequence), or about 4.4 kb (excluding the ITR sequence).

[0063] In some implementations, rAAV carrying GOI can be used in gene therapy to treat diseases or conditions caused by a lack of function of an endogenous gene in the host body, such as a defective version of GOI.

[0064] As used in this article, "gene of interest" or GOI generally refers to a nucleic acid or polynucleotide sequence, such as a gene, an open reading frame (ORF), or a protein or RNA such as siRNA, miRNA, shRNA, etc. However, in some cases or contexts, the term GOI also refers to a protein (encoded by the GOI), or a disease or indication that can be remedied by the GOI, or a disease or indication that can (but is not necessarily) be caused by the loss of function of the GOI.

[0065] For example, the gene GALGT2 encodes the protein GalNActransferase (β-1,4-N-acetylgalactosamine galactosyltransferase), an enzyme that transfers complex sugar molecules to certain proteins, including dystrophin. Under normal circumstances, GalNActransferase is only found at the neuromuscular junction (NMJ), where some components of the dystrophin-associated proteoglycan complex differ from those elsewhere in the muscle. Importantly, at the NMJ, dystrophin-associated protein (Utrophin) is present instead of dystrophin. In muscular dystrophy... mdx In a mouse model, viral gene transfer of GALGT2 resulted in the expression of GalNAc transferase across the entire muscle membrane, rather than just at the normally expressed domain of NMJ, and led to the upregulation of dystrophin-associated proteins across the entire muscle fiber. mdx In mice, this expression corrects for muscle dysfunction to the same extent achievable with minimal dystrophin gene expression. Furthermore, in mouse models of other muscular dystrophys, including LGMD2A and congenital muscular dystrophy (MDC1A), GALGT2 overexpression corrects for muscle pathology. Therefore, GALGT2 is a GOI for treating muscular dystrophys such as DMD, BMD, LGMD2A, and MDC1A, even though GALGT2 itself is not necessarily defective in patients requiring treatment.

[0066] In another example, Sarcolipin (SLN) inhibits muscle / endoplasmic reticulum (SR) Ca. 2+ ATPase (SERCA), and in DMD patients and animal models (such as DMD) mdx Abnormal increases were observed in the muscles of a mouse model. SLN levels were reduced via AAV9-mediated RNA interference in severely ill patients with dystrophin / dystrophin-associated protein double mutants (mdx:utr). - / - In a DMD mouse model, SLN RNAi alleviated muscular dystrophy pathology, including attenuation of muscle pathology and improvement of diaphragmatic, skeletal, and cardiac function. Therefore, the coding sequence of SLN RNAi is the GOI for rescuing DMD.

[0067] Therefore, a GOI can be a gene (or protein) that, when expressed, replaces a mutated, damaged, or inactivated gene or protein. A GOI can be a gene (or protein) that, when expressed, assists a process already functioning that requires modification for the treatment of a disease, disorder, or dysfunction. A GOI nucleic acid sequence can be DNA, RNA, or a synthetic nucleic acid molecule. A GOI can be a protein, enzyme, structural protein, functional protein, or an adaptive protein based on cellular function. GOIs can provide therapeutic benefits or treatments for diseases, disorders, or dysfunctions.

[0068] In some implementations, the GOI may be CRISPR-Cas9, Cas13, TALEN, or other genetically based gene-editing proteins that are required for intracellular delivery to achieve their intended activity.

[0069] As used in this article, any and all GOIs may require codon optimization via known computer-based algorithms to improve expression and activity.

[0070] Therefore, rAAV produced using the capsid of a tested virus (e.g., a modified VP1 capsid) can encode a gene of interest (GOI) that can be used, for example, in gene therapy to treat diseases or conditions. Representative (non-restrictive) GOIs may include: genes responsible for defects in LGMD2E (limb-girdle muscular dystrophy type 2E), LGMD2D (limb-girdle muscular dystrophy type 2D), LGMD2C (limb-girdle muscular dystrophy type 2C), LGMD2B (limb-girdle muscular dystrophy type 2B), LGMD2L (limb-girdle muscular dystrophy type 2L), and LGMD2I (limb-girdle muscular dystrophy type 2I); or genes concerning Naglu (α-N-acetylglucosamine glycosidase for Sanfilippo syndrome or mucopolysaccharidosis type IIIB (MPS IIIB)), sulfonamide SGSH (for mucopolysaccharidosis type IIIA or MPS IIIA), factor IX, factor VIII, and tubulin 1. Genes or coding sequences for (MTM1), survival motor neuron (SMN, for spinal muscular atrophy or SMA), GalNAc transferase GALGT2, calpain-3 (CAPN-3), acid α-glucosidase (GAA, for Pompe disease), α-galactosidase A or GLA (for Fabry disease), glucocerebrosidase, dystrophin, or microdystrophin.

[0071] In some implementations, GOI is the dystrophin microgene.

[0072] In some embodiments, the miniature dystrophin gene is any of the following patents described: US7,906,111, US7,001,761, US7,510,867, US6,869,777, US8,501,920, US7,892,824, PCT / US2016 / 013733, US10,166,272 (all incorporated herein by reference). In some embodiments, the miniature dystrophin gene can be encapsulated within an rAAV virion, for example, with a size not exceeding about 4.7 kb.

[0073] In some embodiments, the micro dystrophin gene contains spectrin-like repeat sequences R16 and R17 within its coding sequence, which are capable of restoring the activity of nitric oxide synthase (nNOS) on the sarcolemma (such as those described in US7,892,824).

[0074] In some embodiments, the miniature dystrophin gene comprises the coding sequences for the full-length dystrophin R1, R16, R17, R23, and R24 spectrin-like repeat sequences (i.e., SR1, SR16, SR17, SR23, and SR24, respectively), such as the miniature dystrophin described in PCT / US2016 / 013733 (incorporated herein by reference). In some embodiments, the miniature dystrophin gene does not encode any other spectrin-like repeat sequences of the full-length dystrophin other than SR1, SR16, SR17, SR23, and SR24.

[0075] In some embodiments, the miniature dystrophin gene is described in US7,906,111, US7,001,761, US7,510,867, US6,869,777, US8,501,920, US7,892,824, or US10,166,272 or PCT / US2016 / 013733 (all incorporated herein by reference). For example, PCT / US2016 / 013733 (WO2016 / 115543A2) provides a miniature dystrophin gene operatively linked to a regulatory cassette, wherein the miniature dystrophin gene encodes a protein comprising: an N-terminal actin-binding domain; a β-dystrophin-binding domain; and a spectrin-like repeat domain comprising at least four spectrin-like repeats, wherein two of the at least four spectrin-like repeats comprise a neuronal nitric oxide synthase-binding domain. In some embodiments, the at least four spectrin-like repeat sequences include spectrin-like repeat sequence 1 (SR1), spectrin-like repeat sequence 16 (SR16), spectrin-like repeat sequence 17 (SR17), and spectrin-like repeat sequence 24 (SR24). In some embodiments, the protein encoded by the mini-dystrophin gene further includes at least a portion of a hinge domain, such as at least one of a hinge 1 domain, a hinge 2 domain, a hinge 3 domain, a hinge 4 domain, and a hinge-like domain. In some embodiments, the mini-dystrophin gene comprises, in N-terminal to C-terminal order: hinge 1 domain (H1), spectrin-like repeat sequence 1 (SR1), spectrin-like repeat sequence 16 (SR16), spectrin-like repeat sequence 17 (SR17), spectrin-like repeat sequence 24 (SR24), and hinge 4 domain (H4). In some embodiments, H1 is directly coupled to SR1. In some embodiments, SR1 is directly coupled to SR16. In some embodiments, SR16 is directly coupled to SR17. In some embodiments, SR17 is directly coupled to SR24. In some embodiments, SR24 is directly coupled to H4. In some embodiments, the protein encoded by the microdystrophin gene further comprises, between SR1 and SR16, spectrin-like repeat sequence 2 (SR2) and spectrin-like repeat sequence 3 (SR3) in N-terminal to C-terminal order. In some embodiments, SR1 is directly coupled to SR2, and SR2 is further coupled to SR3. In some embodiments, H1 is directly coupled to SR1, SR1 is directly coupled to SR16, SR16 is directly coupled to SR17, SR17 is directly coupled to SR23, SR23 is directly coupled to SR24, and SR24 is directly coupled to H4.

[0076] In some embodiments, the regulatory cassette is selected from the group consisting of the CK8 promoter and the cardiac troponin T (cTnT) promoter. In some embodiments, the protein encoded by the mini dystrophin gene has between five and eight spectrin-like repeat sequences. In some embodiments, the protein encoded by the mini dystrophin gene has at least 80% or 90% sequence identity with the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 5 of WO2016 / 115543A2 (incorporated herein by reference).

[0077] Diseases or conditions that may benefit from rAAV containing the tested modified VP1 capsid include: Huntington's disease, X-linked myotubular myopathy (XLMTM), acid maltase deficiency (e.g., Pompe disease), spinal muscular atrophy (SMA), myasthenia gravis (MG), amyotrophic lateral sclerosis (ALS), Friedrich's ataxia, mitochondrial myopathy, muscular dystrophy (Duchenne muscular dystrophy, myotonic dystrophy, Becker's muscular dystrophy (BMD), limb-girdle muscular dystrophy (LGMD), facioscapulohumeral muscular dystrophy (FSH), congenital muscular dystrophy). Malnutrition (CDM), Oculopharyngeal Muscular Dystrophy (OPMD), Distal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy (EDMD), Mucopolysaccharidosis (MPS), Metachromatic Leukodystrophy (MLD), Batten's Disease, Rett Syndrome, Krabbe's Disease, Canavan Disease, Hereditary Retinoschisis, Achromatopsia (CNGB3 and CNGA3), X-linked Retinitis Pigmentosa, Age-related Macular Degeneration, Vascular Macular Degeneration, Pompe disease, Fabry disease, MPS MPS I, MPS II, MPS IIIA, MPS IIIB, Gaucher's disease, Dannon's disease, A1At deficiency, Friedrich's ataxia, Wilson's disease, Bedouin's disease (CLN1, CLN3, CLN6, CLN8), Wolman's disease, Tay-Sachs' disease, Niemann-Lick's disease type C, CDKL5 deficiency, β-thalassemia, sickle cell disease.

[0078] In some embodiments, diseases or conditions that may benefit from the rAAV of the present invention may include: Becker muscular dystrophy (BMD), congenital muscular dystrophy (CMD), Bethlem CMD, Fukuyama CMD, muscle-ocular-cerebromyopathy (MEBs), ankylosing spondylitis, Ullrich CMD, Walker-Warburg syndrome (WWS), Duchenne muscular dystrophy (DMD), Emery-Dreifuss muscular dystrophy (EDMD), facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD), myotonic dystrophy (DM), oculopharyngeal muscular dystrophy (OPMD), motor neuron diseases including ALS (amyotrophic lateral sclerosis), spinal-bulbar muscular atrophy (SBMA), and spinal muscular atrophy (SMA).

[0079] In some embodiments, diseases or conditions that may benefit from the rAAV of the present invention may include ion channel disorders, which are typically characterized by muscle weakness, lack of muscle tone, or occasional muscle paralysis. These include Andersen-Tawil syndrome, hyperkalemic periodic paralysis, hypokalemic periodic paralysis, congenital myotonia, Becker's myotonia, Thomsen's myotonia, congenital paramyotonia, and potassium-induced myotonia.

[0080] In some embodiments, diseases or conditions that may benefit from the rAAV of the present invention may include mitochondrial diseases, which occur when structures that produce energy for the cell malfunction. Such diseases include: Friedrich's ataxia (FA), mitochondrial myopathy, Kearns-Sayre syndrome (KSS), Leigh syndrome (subacute necrotizing encephalomyopathy), mitochondrial DNA depletion syndrome, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), myoclonic epilepsy with irregularly red fibers (MERRF), neuropathy, ataxia and retinitis pigmentosa (NARP), Pearson syndrome, and progressive extraocular muscle palsy (PEO).

[0081] In some embodiments, diseases or conditions that may benefit from the rAAV of the present invention may include myopathy, a muscle disease in which muscle fibers fail to function properly, resulting in muscle weakness. Myopathy includes: gait myopathy, central nucleus myopathy, congenital myopathy with fibrous asymmetry, core myopathies, central core myopathies, multiple microcore myopathies, myosin deposition myopathy, myotubular myopathy, rod body myopathy, distal myopathy, GNE myopathy / Nonaka myopathy / hereditary inclusion body myopathy (HIBM), Laing distal myopathy, Markesberg-Griggs late-onset distal myopathy, Miyoshi myopathy, Udd myopathy / tibial muscular dystrophy, distal vocal cord and pharyngeal myopathy, Welander distal myopathy, endocrine myopathy, hyperthyroid myopathy, hypothyroid myopathy, and inflammation. Symptomatic myopathy, dermatomyositis, inclusion body myositis, polymyositis, metabolic myopathy, acid maltase deficiency (AMD, Pompe disease), carnitine deficiency, carnitine palmityltransferase deficiency, debranching enzyme deficiency (Cori disease, Forbes disease), lactate dehydrogenase deficiency, myoadenylate deaminase deficiency, phosphofructokinase deficiency (Tarui disease), glycerol phosphokinase deficiency, glycerol phosphomaltase deficiency, phosphorylase deficiency (McArdle disease), myofibromyopathy (MFM), and scapular myopathy.

[0082] In some embodiments, diseases or conditions that may benefit from the rAAV of the present invention may include neuromuscular junction diseases caused by the disruption, malfunction, or absence of one or more key proteins involved in signal transmission between muscles and nerves. Such diseases include: congenital myasthenia gravis (CMS), Lambert-Eaton myasthenia gravis (LEMS), and myasthenia gravis (MG).

[0083] In some embodiments, diseases or conditions that may benefit from the rAAV of the present invention may include peripheral nerve diseases, wherein motor and sensory nerves connecting the brain and spinal cord to other parts of the body are affected, resulting in impaired sensory, motor, or other functions. Such diseases include: Charcot-Marie-Tooth disease (CMT), giant axonal neuropathy (GAN), cachexia, and age-related muscle atrophy.

[0084] 4. Production of rAAV rAAVs having the modified VP1 capsid of the present invention can be produced using any standard rAAV production method, typically using a producer cell line, provided that the method / producer cell line is modified to provide a modified VP1 capsid protein in place of the wild-type VP1 capsid (or at least contain the modified VP1 capsid protein in addition to the white wild-type VP1 capsid).

[0085] Several strategies with different underlying principles have been used in rAAV production, and all of them can be used to produce test rAAV.

[0086] In some implementations, the tested rAAV is produced based on a helper virus-free transient transfection method using all cis and trans components (vector plasmid and encapsulation plasmid, along with helper genes isolated from adenovirus) from suitable host cells such as 293 cells. The transient transfection method is simple in terms of vector plasmid constructs and produces a high-titer AAV vector free of adenovirus. The modified VP1 capsid protein can be encoded by a plasmid used during transient transfection in the producer cell line.

[0087] In some implementations, rAAV is produced using an AAV production system based on recombinant herpes simplex virus (rHSV), which utilizes an rHSV vector to combine an AAV vector with... Rep and Cap The gene (i.e., the modified VP1 capsid gene of this invention) is delivered into the cell. Modified cap Genes can exist in rHSV vectors, which also serve as rAAV genome hosts.

[0088] In some implementations, a baculovirus system is used to produce the test rAAV, which requires simultaneous infection of insect cells with several baculovirus vectors to deliver the AAV vector cartridge. Rep and Cap Gene (i.e., the modified VP1 capsid gene of the present invention).

[0089] In some implementations, the tested rAAV is produced based on certain AAV-producing cells derived from, for example, HeLa, A549, or HEK293 cells, which stably carry AAV. Rep / cap The gene (i.e., the modified VP1 capsid gene of the present invention). The AAV vector cartridge can be stably integrated into or introduced into the host genome by the adenovirus contained in the cartridge.

[0090] In some implementations, such producer cell lines for rAAV production contain an rAAV provirus encoding a GOI with an AAVITR sequence flanking it, wherein the rAAV provirus is integrated into the genome of the producer cell line for rAAV production.

[0091] 5. Treatment of muscular dystrophy with rAAV rAAV containing the modified VP1 capsid of this invention can be used in gene therapy to treat various forms of muscular dystrophy, such as Duchenne muscular dystrophy (DMD), myotonic dystrophy, Becker's muscular dystrophy (BMD), limb-girdle muscular dystrophy (LGMD), facioscapulohumeral muscular dystrophy (FSH), congenital muscular dystrophy (CDM), oculopharyngeal muscular dystrophy (OPMD), distal muscular dystrophy, Emery-Dreifuss muscular dystrophy (EDMD), etc. In some embodiments, the muscular dystrophy is either DMD or BMD.

[0092] Therefore, one aspect of the present invention provides a method for treating muscular dystrophy (such as DMD and BMD) in a subject with such need, the method comprising administering to the subject a therapeutically effective amount of a recombinant AAV (rAAV) vector encoding a functional version of a gene defective in muscular dystrophy, such as the microdystrophin gene, wherein the rAAV contains any modified VP1 capsid protein of the present invention.

[0093] In some embodiments, the miniature dystrophin gene is the miniature dystrophin gene described in US7,906,111, US7,001,761, US7,510,867, US6,869,777, US8,501,920, US7,892,824, PCT / US2016 / 013733 or US10,166,272 (all of which are incorporated herein by reference).

[0094] In some embodiments, the miniature dystrophin gene contains the coding sequences for the full-length dystrophin R1, R16, R17, R23, and R24 spectrin-like repeat sequences (such as the miniature dystrophin described in PCT / US2016 / 013733).

[0095] In some embodiments, the method further includes producing the test rAAV and then administering the rAAV thus produced to the subject.

[0096] Example Example 1: In vitro assay comparing the tested AAV-SLB101 with AAV9 and AAV8 This experiment compares the effect of the tested rAAV capsid on the expression of GOI from the recombinant AAV vector in muscle cells with that of AAV8 and AAV9.

[0097] Specifically, C2C12 cells (immortalized mouse myoblast cell line) were transduced with rAAV vectors expressing dystrophin, encapsulated in AAV9, AAV8, and the test capsid AAV-SLB101 (SEQ ID NO: 14), at three different multiples of infection (MOIs). Cells were harvested 72 hours after transduction, and dystrophin expression was measured by ELISA. Data showed that... Figures 1A to 1C In, and in Figure 1A and 1B In the mean ± SD, each data point is represented by a one-way ANOVA test to determine statistical significance in comparisons with the AAV9 data at each MOI.

[0098] exist Figure 1A In this study, dystrophin expression was determined based on the number of micrograms (μg) of dystrophin expressed per milliliter. Data showed that, compared to AAV9, the tested rAAV capsid was associated with significantly higher expression of GOI (e.g., dystrophin) in C2C12 muscle cells. Although no direct statistical comparison was performed, the data also indicated that, compared to AA8, the tested rAAV capsid was associated with significantly higher expression of GOI (e.g., dystrophin) in C2C12 muscle cells.

[0099] exist Figure 1B In this study, the expression of dystrophin minima was determined based on the integral sum of immunofluorescence intensities. The data again showed that, compared to AAV9, the tested rAAV capsid was associated with significantly higher expression of GOI (e.g., dystrophin minima) in C2C12 muscle cells. Although no direct statistical comparison was performed, the data also indicated that, compared to AA8, the tested rAAV capsid was associated with significantly higher expression of GOI (e.g., dystrophin minima) in C2C12 muscle cells.

[0100] exist Figure 1C In this study, C2C12 cells were transduced similarly with rAAV vectors expressing dystrophin encapsulated in AAV9, AAV8, and the test capsid AAV-SLB101 at three different multiplici of infection (MOIs). Cells were fixed and immunostained 72 hours post-transduction, and dystrophin expression was visualized by immunofluorescence (IF). Uninfected / untreated cells were stained with green fluorescence against myosin heavy chain (MyHC). Cell nuclei were stained with DAPI. The data visually confirmed that, at all tested dose levels, the test rAAV capsid demonstrated a stronger ability to directly express GOIs (e.g., dystrophin) in C2C12 muscle cells compared to both AAV9 and AAV8 capsids.

[0101] In another experiment, C2C12 cells were transduced using the same three AAVs as described above, but only at the lowest MOI. Cells were harvested 96 hours after transduction and dystrophin expression was measured. The data were then normalized to AAV9 and plotted on [data missing]. Figure 1D In, and indicate the multiplier change in the insertion point. Figure 1D The table shows that AAV-SLB101 showed significantly higher expression of dystrophin than AAV9 (p < 0.0001). Statistical analysis was performed using a standard one-way ANOVA.

[0102] In another experiment, the same three AAVs as described above were used, but only at the lowest MOI to transduce DMD cells derived from patients. Cells were harvested 72 hours after transduction and dystrophin expression was measured. The data were then normalized to AAV9 and plotted on [data missing]. Figure 1E In, and indicate the multiplier change in the insertion point. Figure 1E The table shows that AAV-SLB101 showed significantly higher expression of dystrophin than AAV9 (p < 0.0001). Statistical analysis was performed using a standard one-way ANOVA.

[0103] Example 2: In vitro titer determination in C2C12 and DMD cells C2C12 cells were transduced with rAAV vectors expressing dystrophin, encapsulated in AAV9, AAV8, and the test capsid AAV-SLB101, at three different multiples of infection (MOIs). Cells were harvested 72 hours post-transduction, and dystrophin expression was measured. Data are presented as mean ± SD. Statistical analysis was determined by one-way ANOVA in comparisons with AAV9 at each MOI.

[0104] exist Figure 2A The figure above shows that, compared to rAAV with an AAV9 capsid, rAAV with the tested rAAV capsid achieved statistically significantly greater expression of dystrophin at two doses (3E6 and 7.5E5) in differentiated C2C12 cells. Figure 2A The figure below shows the same results for AAV9 after normalization to the same MOI, presented as a bar chart. Specifically, at the higher dose of 3E6, the expression level using the test coating was 8.0-fold higher. At the lower dose of 7.5E5, the expression level using the test coating was 10.6-fold higher.

[0105] Repeat similar experiments in DMD cells (i.e., Mouly cells) derived from patients.

[0106] Specifically, DMD Mouly cells derived from patients were transduced at three different multiples of infection (MOIs) using vectors expressing dystrophin encapsulated in AAV9, AAV8, and the test capsid AAV-SLB101. Cells were harvested 72 hours post-transduction and dystrophin expression was measured. Data are presented as mean ± SD. Statistical analyses were determined by one-way ANOVA in comparisons with AAV9 at each MOI.

[0107] exist Figure 2B The upper figure shows that, compared to rAAV with an AAV9 capsid, rAAV with the tested rAAV capsid achieved statistically significantly greater expression of dystrophin at two doses (3E6 and 7.5E5) in differentiated DMD Mouly cells. Outliers were removed from the data. Figure 2B The figure below shows the same results for AAV9 after normalization to the same MOI, presented as a bar chart. Specifically, at the higher dose of 3E6, the expression level using the test capsid was 3.1-fold higher. At the lower dose of 7.5E5, the expression level using the test capsid was 4.1-fold higher.

[0108] Example 3: In vitro comparison of the test AAV-SLB101 capsid with AAV9. This experiment used a mouse model of DMD, namely mdx Mice were used to demonstrate the superior expression level of microdystrophin in rAAV with the test capsid compared to that in rAAV with the AAV9 capsid.

[0109] To about 5 to 6 weeks old mdx Mice were administered a systemic (intravenous) injection (1E14 vg / kg) of an rAAV vector expressing dystrophin minima, encapsulated in either the test capsid AAV-SLB101 or AAV9. Mice were necropsed 2–4 weeks post-injection (N = 3 at 2 weeks; and N = 4 at 4 weeks), and tissues were harvested to quantify vector biodistribution and dystrophin minima expression. Statistical data for all groups compared to AAV9 were determined using individual Welch t-tests.

[0110] Figure 3AThe results showed that AAV-SLB101 had significantly higher bioavailability in the heart (p < 0.001) and quadriceps (“quad”) (p < 0.01) at one or two time points (i.e., day 15 and day 29), and a trend toward higher vg in the diaphragm (particularly on day 15). Meanwhile, AAV-SLB101 had significantly lower vg in the liver than AAV9 (p < 0.01). Data are presented as mean ± SD. Statistical analysis was determined by one-way ANOVA in comparisons with AAV9 at each time point. No significant differences were observed in the brain (data not shown).

[0111] Figure 3B The results showed that, on day 29, regarding expression in multiple peripheral tissues, there was no observable difference between rAAV encapsulated in the test capsid and rAAV encapsulated in the AAV9 capsid, as expected due to the use of a muscle-specific promoter. The peripheral tissues tested included the lung, spleen, kidney, and brain.

[0112] Figure 3C The results showed that, at both day 15 and day 29, rAAV encapsulated in the test AAV-SLB101 capsid achieved significantly higher expression of dystrophin in all three tested muscle tissues (i.e., heart (cardiac muscle) (p < 0.05), diaphragm (smooth muscle), and quadriceps (skeletal muscle) (p < 0.05)) compared to rAAV encapsulated in the AAV9 capsid. Neither construct showed significant expression in the liver. Data are presented as mean ± SD. Statistical analysis was determined by one-way ANOVA in comparisons with AAV9 at each time point.

[0113] The data above indicate that, in in vitro potency assays, the tested AAV-SLB101 capsid exhibited excellent GOI (e.g., dystrophin minima) expression efficiency in both cultured C2C12 muscle cells and patient-derived DMD Mouly cells. In vitro results were also validated in a mouse DMD model. mdx In vivo biodistribution studies performed in mice have confirmed this.

[0114] Specifically, in mdx In vivo biodistribution studies in mice showed that the tested AAV-SLB101 capsid had significantly higher biodistribution in the heart and quadriceps muscle than AAV9 at both test time points (i.e., day 15 and day 29), and showed a trend toward higher vg in the diaphragm on day 15. Furthermore, the tested AAV-SLB101 capsid had significantly lower vg in the liver, which is an unintended target tissue for dystrophin expression.

[0115] Regarding the expression of microdystrophin, the AAV-SLB101 capsid showed significantly higher expression levels than AAV9 in all three types of muscle tissue tested.

[0116] Example 4: Characterization of additional modified AAV-SLBC capsids Additional modified AAV9 capsids (including AAV-SLB102 to AAV-SLB112) and two modified capsids (AAV-SLB113 and AAV-SLB-114) with similar insert sequences but different neighboring / flank sequences were constructed, and their potency was tested compared to wild-type AAV9 and AAV-SLB101. The insert sequences of AAV-SLB102 to AAV-SLB112 are SEQ ID NO: 2 to SEQ ID NO: 12, respectively. For multiple sequence alignments of the tested constructs relative to wild-type AAV9 and AAV-SLB101 sequences, see [link to documentation]. Figure 6 .

[0117] In the first experiment, based on triple transfection of Adhesion 293T cells followed by stepwise iodixanol ultracentrifugation for purification, the production yields of various capsid constructs were compared with those of wild-type AAV9 capsids and AAV-SLB101. The measured production yields were plotted on [data missing]. Figure 4 In the meantime, with a few exceptions, most constructs have similar (but slightly lower) yields compared to wild-type AAV9.

[0118] A series of in vitro characterization experiments were performed to compare additional tested modified VP1 capsids with wild-type AAV9 and previously tested AAV-SLB101 in C2C12 cells. Results are reported in [Month]. Figures 5A to 5C middle.

[0119] Specifically, the amount of AAV bound to the cell surface of C2C12 cells was measured by qPCR on DNA isolated after incubation at 4°C for 1 hour. Figure 5A The results showed that AAV-SLB101 (p < 0.0001), AAV-SLB112 (p < 0.01), and AAV-SLB114 (p < 0.001) all bound significantly more strongly to C2C12 cells than AAV9, while the remaining constructs all exhibited binding similar to wild-type AAV9. Statistical analysis was performed using a standard one-way ANOVA.

[0120] However, C2C12 cells appear to exhibit significant differences in the somewhat isotropic uptake of viral vectors with different modified capsids. Specifically, in Figure 5BIn this study, qPCR was performed on DNA isolated after incubation at 4°C for 1 hour and then at 37°C for another 1 hour to measure the quantification of AAV uptake in C2C12 cells. The results showed that AAV-SLB101, 102, 108, 111, 112, 113, and 114 were uptaken by C2C12 cells significantly more than (approximately 20 to 40 times more) AAV9 (p < 0.0001). Other constructs tested appeared to have comparable cellular uptake to AAV9. Statistical analysis was performed using a standard one-way ANOVA.

[0121] Finally, Figure 5C In this study, C2C12 cells were transduced using vectors expressing dystrophin encapsulated in AAV9, AAV-SLB101, and thirteen other AAV capsids. Cells were harvested 96 hours post-transduction, and dystrophin expression was measured. Data were normalized to AAV9, and fold changes were indicated by the number of cells inserted into the AAV9 capsid. Figure 5C The table below shows that AAV-SLB101, 102, 111, 112, and 113 exhibited the highest expression of dystrophin compared to AAV9 (p < 0.0001), while AAV-SLB109 and 114 resulted in expression only slightly higher than AAV9 (p < 0.001). Statistical analysis was performed using a standard one-way ANOVA.

[0122] It is noteworthy that although SLB101, SLB113, and SLB114 all share the same RGDLGLS insertion sequence, and the differences are primarily in the flanking sequences, SLB101 appears to result in a significantly higher level of dystrophin expression (8.87:4.11:1.94). That is, SLB101 is 116% of SLB113, while SLB113 itself is 112% of SLB114.

[0123] In summary, the data above show that at least one tested modified VP1 capsid, AAV-SLB101, exhibits superior efficiency in in vitro assays performed in mouse and DMD human skeletal muscle cells compared to wild-type AAV9. This also resulted in increased biodistribution in the quadriceps and heart, and in vivo expression of dystrophin microsporin, and decreased biodistribution in the liver, compared to AAV9. An expanded genome of the tested modified AAV9 capsid also identified at least two additional candidate genes, AAV-SLB102 and AAV-SLB111, which performed similarly to AAV-SLB101 in in vitro assays concerning binding, uptake, and dystrophin microsporin expression in C2C12 cells.

[0124] Example 5: Functional importance of the sequence surrounding the inserted peptide This embodiment demonstrates the following surprising finding: the function of the modified AAV9 capsid depends not only on the identity of the short peptide inserted into the wild-type AAV9 capsid protein, but also on the sequence surrounding the inserted short peptide.

[0125] Functional comparisons were performed using three representative modified AAV9 capsids: SLB-101, SLB-113, and SLB-114. See also Figure 6 Sequence alignment was performed. All three sequences contain the same 7-residue core sequence RGDLGLS, but differ slightly in the N-terminal and C-terminal sequences immediately surrounding this 7-residue core sequence. In SLB-101, the 7-residue core sequence is inserted between residues 588 and 589 of the wild-type AAV9 VP1 capsid (i.e., there are no changes to the wild-type AAV9 VP1 sequence other than the inserted 7-residue core sequence). See also Figure 6 Local sequence alignment between wild-type AAV9 and SLB-101.

[0126] In contrast, in SLB-113 and SLB-114, relative to the 7-residue core sequence, there are additional changes at two locations: within the immediate N-terminal 3 to 4 residues and within the immediate C-terminal 4 to 5 residues (see [link to original text]). Figure 6 Overall, the sequences of SLB-113 and SLB-114 appear to be more similar to each other than those of SLB-101.

[0127] Figure 5A The results showed that, in vitro, these capsids exhibited varying abilities to bind to C2C12 cells. SLB-101 and SLB-114 both bound to C2C12 cells significantly more strongly than wild-type AAV9, while SLB-113 showed no significant difference.

[0128] exist Figure 5B In comparison with SLB-113 and SLB-114, C2C12 cells infected with the AAV9 variant SLB-101 appeared to express the encoded micro dystrophin at surprisingly higher levels.

[0129] To demonstrate that these in vitro results were not due to artifacts associated with the cell line used (i.e., C2C12 cells), a model DMD was used. mdx In vivo expression studies were designed in mice. Specifically, mice aged 5 to 6 weeks were used. mdx Mice were injected with a single dose of 1E14 vg / kg of wild-type AAV9 or AAV9 with a variant capsid of SLB-101, SLB-102, SLB-113, or SLB-114. SLB-102 was included, but it had a different inserted short peptide (see [link to article]). Figure 6Mice that received the injection underwent necropsy 2 to 4 weeks post-injection (N = 3 @ 2 weeks, and N = 3–4 @ 4 weeks). The biodistribution of the virus via MSD and microdystrophin was examined in the four groups of mice and compared with the wild-type control group.

[0130] Figure 7 The results showed that, compared with wild-type AAV9, both SLB-101 and SLB-114 had significantly increased biodistribution to the quadriceps (skeletal) muscle (6.78-fold and 8.09-fold, respectively). Meanwhile, the modest increases in SLB-102 and SLB-113 were not statistically significant. Similar observations were made in the diaphragm (skeletal muscle).

[0131] In the heart, the biodistribution of SLB-101 was significantly higher than that of wild-type AAV9 (4.35-fold). SLB-114 also tended to be higher (2.48-fold), but this was not statistically significant. Moreover, both SLB-102 and SLB-113 had roughly the same biodistribution compared to the AAV9 control.

[0132] Interestingly, while all AAV9 variants showed lower liver distribution, only SLB-114 showed a statistically significant lower distribution. See also Figure 7 .

[0133] The extended biological distribution in a large number of other organs was also examined. Figure 8 The results showed that SLB-101 had a statistically significantly lower distribution in the brain, while the distribution in the lungs, spleen, and kidneys appeared to be comparable to that of wild-type AAV9, but SLB-101 was higher in the kidneys and SLB-114 was higher in the spleen.

[0134] exist Figure 9 In this study, the expression of small dystrophin proteins (SLB-101 and SLB-114) in the heart, quadriceps muscle, and diaphragm was examined. Compared with wild-type AAV9, SLB-101 and SLB-114 showed statistically higher expression in all three tissues, while SLB-102 was not significantly expressed in any tissue. Meanwhile, SLB-113 was only significantly expressed in the diaphragm, and not statistically significantly higher than AAV9 in the other two tissues.

[0135] These data suggest that at least the biodistribution and expression of the small dystrophin are influenced by the surrounding sequence, as SLB-101, SLB-113, and SLB-114 all have the same 7-residue core sequence insertion.

Claims

1. A modified adeno-associated virus (mAAV) capsid polypeptide comprising a polypeptide selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 12, wherein, The polypeptide is inserted between residues 588 and 589 of the wild-type AAV9 VP1 capsid, or between two corresponding residues of the non-AAV9 wild-type Clad F (e.g., AAVhu.32), wild-type Clad A (e.g., AAV6), or wild-type Clad E (e.g., AAV8, AAVrh.10, or AAVrh.74) VP1 capsid.

2. The mAAV capsid polypeptide according to claim 1, comprising the polypeptide of SEQ ID NO: 1, SEQ ID NO: 11 or SEQ ID NO:

12.

3. A modified adeno-associated virus (mAAV) capsid polypeptide comprising, substantially comprising, or comprising the polypeptide of SEQ ID NO:

1.

4. A modified adeno-associated virus (mAAV) capsid polypeptide comprising, substantially comprising, or comprising the polypeptide of SEQ ID NO:

11.

5. A modified adeno-associated virus (mAAV) capsid polypeptide comprising, substantially comprising, or comprising the polypeptide of SEQ ID NO:

12.

6. A recombinant adeno-associated virus (rAAV) comprising the mAAV capsid polypeptide according to any one of claims 1 to 5.

7. The rAAV according to claim 6, wherein, The VP1 capsid of the rAAV is composed of or substantially composed of the mAAV capsid polypeptide according to any one of claims 1 to 5.

8. The rAAV according to claim 6 or 7, wherein, The rAAV contains genes of interest (GOIs) flanked by a pair of AAV ITR sequences.

9. The rAAV according to claim 8, wherein, The pair of AAV ITR sequences is either an AAV2 or an AAV9 ITR sequence.

10. The rAAV according to claim 8 or 9, wherein, The genes of interest (GOIs) include: genes responsible for or defective in LGMD2E (limb-girdle muscular dystrophy type 2E), LGMD2D (limb-girdle muscular dystrophy type 2D), LGMD2C (limb-girdle muscular dystrophy type 2C), LGMD2B (limb-girdle muscular dystrophy type 2B), LGMD2L (limb-girdle muscular dystrophy type 2L), and LGMD2I (limb-girdle muscular dystrophy type 2I); or genes related to Naglu (α-N-acetylglucosamine glycosidase, for Sanfilippo syndrome or mucopolysaccharidosis type IIIB (MPS IIIB)), sulfonamide SGSH (for mucopolysaccharidosis type IIIA or MPS IIIA), factor IX, factor VIII, myotubulein 1 (MTM1), motor neuron survival (SMN, for spinal muscular atrophy or SMA), GalNActransferase GALGT2, and calpain-3. (CAPN-3), acid α-glucosidase (GAA, for Pompe disease), α-galactosidase A or GLA (for Fabry disease), glucocerebrosidase, dystrophin or microdystrophin gene or coding sequence.

11. The rAAV according to claim 8 or 9, wherein, The GOI encodes a small dystrophin.

12. The rAAV according to claim 11, wherein, The micro dystrophin is the micro dystrophin described in US7,906,111, US7,001,761, US7,510,867, US6,869,777, US8,501,920, US7,892,824, PCT / US2016 / 013733 or US10,166,272.

13. The rAAV according to claim 12, wherein, The micro dystrophin comprises the coding sequences of the R16 and R17 spectrin-like repeat sequences of the full-length dystrophin (such as the coding sequences described in US7,892,824).

14. The rAAV according to claim 13, wherein, The miniature dystrophin comprises the coding sequence of the full-length dystrophin R1, R16, R17, R23, and R24 spectrin-like repeat sequences, or the miniature dystrophin described in PCT / US2016 / 013733 or US10,479,821.

15. The rAAV according to any one of claims 8 to 14, wherein, The GOI is operatively linked to a transcriptional regulatory box, such as a muscle-specific promoter (e.g., the CK8 promoter or the cardiac troponin T (cTnT) promoter).

16. The rAAV according to any one of claims 8 to 15, wherein, The GOI is a miniature dystrophin gene encoding a protein comprising, from N-terminus to C-terminus: an N-terminal actin-binding (AB1) domain, a β-dystrophin-binding domain, a hinge 1 domain (H1), a spectral repeat unit domain comprising five spectral repeat sequences (SR1, SR16, SR17, SR23, and SR24), and a hinge 4 domain (H4), wherein the miniature dystrophin gene is operatively linked to the muscle-specific human muscle creatine kinase CK8 promoter (e.g., SEQ ID NO: 19 of US10,479,821), and wherein the GOI has a pair of AAV2 ITR (inverted terminal repeat) sequences flanking it.

17. A polynucleotide encoding a modified adeno-associated virus (mAAV) capsid polypeptide according to any one of claims 1 to 5, wherein the polypeptide sequence is at least 95%, 96%, 97%, 98%, or 99% identical to the capsid polypeptide.

18. The polynucleotide of claim 17, codon-optimized for mammalian expression.

19. A vector comprising the polynucleotide according to claim 17 or 18.

20. The vector according to claim 19, wherein it is a capsid or viral vector (such as an HSV vector or an AAV vector).

21. A cultured host cell comprising: (a) A recombinant nucleic acid molecule encoding: (1) a modified adeno-associated virus (mAAV) capsid polypeptide according to any one of claims 1 to 5, or (2) a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to (1), wherein the recombinant nucleic acid molecule optionally further comprises a heterologous non-AAV sequence; or, (b) A recombinant adeno-associated virus (rAAV) according to any one of claims 6 to 16.

22. A method for treating a disease or condition such as muscular dystrophy in a subject who requires such treatment, the method comprising administering to the subject a therapeutically effective amount of rAAV according to any one of claims 11 to 16.

23. The method according to claim 22, wherein, Compared to other identical reference rAAVs with wild-type AAV9 VP1 capsids, the GOI of the rAAVs is preferentially expressed in cardiac, skeletal, and / or smooth muscle (e.g., smooth muscle in the diaphragm).

24. The method according to claim 22 or 23, wherein, Compared with other identical reference rAAVs having a wild-type AAV9 VP1 capsid, the GOI of the rAAV was expressed in the liver at a statistically significantly lower level.

25. The method according to any one of claims 22 to 24, wherein, The muscular dystrophy referred to is either DMD (Duchenne muscular dystrophy) or BMD (Becker's muscular dystrophy).

26. The method according to any one of claims 22 to 25, wherein: (1) The muscular dystrophy mentioned is LGMD2E (limb-girdle muscular dystrophy type 2E), LGMD2D (limb-girdle muscular dystrophy type 2D), LGMD2C (limb-girdle muscular dystrophy type 2C), LGMD2B (limb-girdle muscular dystrophy type 2B), LGMD2L (limb-girdle muscular dystrophy type 2L), LGMD2I (limb-girdle muscular dystrophy type 2I), or spinal muscular atrophy or SMA; (2) The disease or condition described is Sanfilippo syndrome or mucopolysaccharidosis type IIIB (MPS IIIB), mucopolysaccharidosis type IIIA or MPS IIIA, Pompe disease or Fabry disease; or, (3) The disease or condition is characterized or caused by a gene defect in the gene encoding factor IX, factor VIII, myotubule 1 (MTM1), GalNAc transferase GALGT2, calpain-3 (CAPN-3) or glucocerebroside lipase.

27. A method for producing rAAV, wherein, The rAAV comprises a mAAV capsid polypeptide according to any one of claims 1 to 5, and the method comprises introducing a GOI encoding a pair of ITR sequences on the flanking side into an rAAV vector to produce or encapsulate a cell line expressing a mAAV capsid polypeptide according to any one of claims 1 to 5.

28. The method according to claim 27, wherein, The production or encapsulation cell lines are infected by an HSV vector encoding the mAAV capsid polypeptide according to any one of claims 1 to 5.

29. The method according to claim 27, wherein, The production or encapsulation cell line is transfected with the coding sequence of the mAAV capsid polypeptide according to any one of claims 1 to 5.

30. The method according to claim 27 or 28, wherein, The cell lines used for production or packaging are HEK293 cells, A549 cells, or HeLa cells.

Citation Information

Patent Citations

  • Efficient systemic treatment of dystrophic muscle pathologies

    US10166272B2

  • Micro-dystrophins and related methods of use

    US10479821B2

  • Mini-dystrophin nucleic acid sequences

    US6869777B2

  • DNA sequences comprising dystrophin minigenes and methods of use thereof

    US7001761B2

  • DNA sequences encoding dystrophin minigenes and methods of use thereof

    US7510867B2